Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity recon…
$13.42-4.96%
报价 2026-11-06
市值
$1.04B
EV
$2.79B
PE (TTM)
80.0x
预期 PE (FY2026)
5.7x
52 周区间距高点 -32.4%
$8.90$19.85
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 2.52 → 2.37（0.9x） | 5.7 |
| FY+32028-12 | 1.0x | 2.52 → 2.47（1.0x） | 5.4 |
毛利率 52% · TTM 收入 $1657M · 基数 EPS 2.52（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IARTIntegra LifeSciences Holdings Corporation | $1.04B | -5.0% | +0.8% | 51% | 80.0x | 12.0x | 10.6x | |
| SEPNSepterna, Inc. | $2.28B | +3.2% | +94.3% | 99.4% | – | – | 16.4x | |
| MRVIMaravai LifeSciences Holdings, Inc. | $2.13B | +7.7% | +14.0% | 34.6% | – | – | – | |
| FTREFortrea Holdings Inc. | $2.08B | +7.3% | -4.4% | 17.1% | – | 34.8x | 12.5x | |
| BFLYButterfly Network, Inc. | $1.7B | +4.9% | +36.1% | 73% | – | – | – | 高增长 |
| TNDMTandem Diabetes Care, Inc. | $1.18B | -6.0% | +7.1% | 56.9% | – | – | – | |
| INMDInMode Ltd. | $767.1M | -0.5% | – | 77.8% | 10.7x | 5.3x | – | Cheap |
| PACBPacific Biosciences of California, Inc. | $700.9M | -7.2% | +6.3% | 36% | – | – | – | |
| BCAXBicara Therapeutics Inc. Common Stock | $572.4M | +5.6% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +10.6% | 46.4% | 10.7x | 20.1x | 14.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $411.2M | $418.8M | $391.9M | $434.9M | $402.1M | $415.6M | $382.7M | $442.6M |
| Gross Margin | 51% | 52.5% | 57.2% | 49.5% | 56.2% | 50.4% | 50.8% | 56.3% |
| Operating Margin | 4.6% | 4.6% | 10.2% | 127.9% | 10% | -123.4% | -4% | 8% |
| Net Income | $14.9M | $4.5M | $-4.6M | $-1.7M | $-5.4M | $-484.1M | $-25.3M | $19.4M |
| Diluted EPS | 0.19 | 0.06 | -0.06 | -0.02 | -0.07 | -6.33 | -0.33 | 0.25 |
| Operating Cash Flow | $96M | $22.8M | $9.8M | $11.8M | $40.9M | $8.9M | $-11.3M | $50.7M |